VEGFA and hepatocellular carcinoma: Recently, systemic therapies, including immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) monoclonal antibodies, have challenged the treatment landscape of unresectable HCC (uHCC) with remarkable survival benefits.